Christopher B. Ehrlich - 30 May 2025 Form 4 Insider Report for CERO THERAPEUTICS HOLDINGS, INC. (CERO)

Reporting relationship: Chairman and CEO, Director
Issuer ticker: CERO
Reported as of: 30 May 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Jun 2025, 17:04:25 UTC
Prior SEC filing: 06 Mar 2025
Next SEC filing: 09 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Andrew Kucharchuk, Attorney-in-Fact

Key filing fact

Christopher B. Ehrlich filed Form 4 for CERO THERAPEUTICS HOLDINGS, INC. (CERO) on 02 Jun 2025.

Key facts

This page summarizes Christopher B. Ehrlich's Form 4 filing for CERO THERAPEUTICS HOLDINGS, INC. (CERO).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 02 Jun 2025, 17:04.

Change

Previous filing in this sequence was filed on 06 Mar 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001293973 Primary reporting owner

Ehrlich Christopher B

Relationship: Chairman and CEO, Director
Address: CERO THERAPEUTICS HOLDINGS, INC., 201 HASKINS WAY, SUITE 230, SOUTH SAN FRANCISCO
Signature: /s/ Andrew Kucharchuk, Attorney-in-Fact
Signature date: 02 Jun 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CERO transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +61,843
Change %
Price: $0.000000
Shares after: 61,842
Date: 30 May 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 61,842
Exercise price: $0.4454
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents the 1/3 time-based portion of an award of options to purchase 185,529 shares, vesting in equal monthly installments on the 4th of each month from July 4, 2025 through December 4, 2025, with the remaining portion subject to performance conditions.

SEC remarks

Exhibit 24 - Power of Attorney.